Serum autoantibodies for the diagnosis and management of autoimmune liver diseases

References

• Agmon-Levin N, Shapira Y, Selmi C et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J. Autoimmun. 34(1), 55–58 (2010).
   PubMed Web of Science ®Google Scholar
• Moroni L, Bianchi I, Lleo A. Geoepidemiology, gender and autoimmune disease. Autoimmun. Rev. 11(6–7), A386–A392 (2012).
   PubMed Web of Science ®Google Scholar
• Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J. Gastroenterol. Hepatol. 18(10), 1118–1128 (2003).
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Tsuneyama K, Fujimoto M et al. Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J. Autoimmun. 30(1–2), 42–50 (2008).
   PubMed Web of Science ®Google Scholar
• Sharma R, Fu SM, Ju ST. IL-2: a two-faced master regulator of autoimmunity. J. Autoimmun. 36(2), 91–97 (2011).
   PubMed Web of Science ®Google Scholar
• Ullal AJ, Reich CF 3rd, Clowse M et al. Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. J. Autoimmun. 36(3–4), 173–180 (2011).
   PubMed Web of Science ®Google Scholar
• Ospelt C, Reedquist KA, Gay S, Tak PP. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? Autoimmun. Rev. 10(9), 519–524 (2011).
   PubMed Web of Science ®Google Scholar
• Conrad K, Roggenbuck D, Reinhold D, Sack U. Autoantibody diagnostics in clinical practice. Autoimmun. Rev. 11(3), 207–211 (2012).
   PubMed Web of Science ®Google Scholar
• Bonaguri C, Melegari A, Ballabio A et al. Italian multicentre study for application of a diagnostic algorithm in autoantibody testing for autoimmune rheumatic disease: conclusive results. Autoimmun. Rev. 11(1), 1–5 (2011).
   PubMed Web of Science ®Google Scholar
• Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J. Gastroenterol. 14(21), 3374–3387 (2008).
   PubMed Web of Science ®Google Scholar
• Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J. Autoimmune Dis. 1(1), 2 (2004).
   PubMedGoogle Scholar
• Krawitt EL. Autoimmune hepatitis. N. Engl. J. Med. 354(1), 54–66 (2006).
   PubMed Web of Science ®Google Scholar
• Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand. J. Gastroenterol. 33(1), 99–103 (1998).
   PubMed Web of Science ®Google Scholar
• Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J. Hepatol. 40(1), 3–7 (2004).
   PubMed Web of Science ®Google Scholar
• Mieli-Vergani G, Heller S, Jara P et al. Autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 49(2), 158–164 (2009).
   PubMed Web of Science ®Google Scholar
• Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31(5), 929–938 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 18(4), 998–1005 (1993).
   PubMed Web of Science ®Google Scholar
• Hennes EM, Zeniya M, Czaja AJ et al.; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48(1), 169–176 (2008).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am. J. Gastroenterol. 97(2), 413–419 (2002).
   PubMed Web of Science ®Google Scholar
• Leung PS, Coppel RL, Ansari A, Munoz S, Gershwin ME. Antimitochondrial antibodies in primary biliary cirrhosis. Semin. Liver Dis. 17(1), 61–69 (1997).
   PubMed Web of Science ®Google Scholar
• Cowling DC, Mackay IR, Taft LI. Lupoid hepatitis. Lancet 271(6957), 1323–1326 (1956).
   PubMed Web of Science ®Google Scholar
• Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME. Definition of human autoimmunity–autoantibodies versus autoimmune disease. Autoimmun. Rev. 9(5), A259–A266 (2010).
   PubMed Web of Science ®Google Scholar
• Whittingham S, Irwin J, Mackay IR, Smalley M. Smooth muscle autoantibody in ‘autoimmune’ hepatitis. Gastroenterology 51(4), 499–505 (1966).
   PubMed Web of Science ®Google Scholar
• Johnson GD, Holborow EJ, Glynn LE. Antibody to smooth muscle in patients with liver disease. Lancet 2(7418), 878–879 (1965).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 24(5), 1068–1073 (1996).
   PubMed Web of Science ®Google Scholar
• Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 35(8), 515–519 (2002).
   PubMed Web of Science ®Google Scholar
• Guéguen P, Dalekos G, Nousbaum JB et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J. Clin. Immunol. 26(6), 495–505 (2006).
   PubMed Web of Science ®Google Scholar
• Renaudineau Y, Dalekos GN, Guéguen P, Zachou K, Youinou P. Anti-α-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin. Rev. Allergy Immunol. 34(3), 321–325 (2008).
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin. Exp. Immunol. 15(3), 331–344 (1973).
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Bianchi FB, Doniach D. Characterization of the microsomal antigen related to a subclass of active chronic hepatitis. Immunology 26(3), 589–601 (1974).
   PubMed Web of Science ®Google Scholar
• Crivelli O, Lavarini C, Chiaberge E et al. Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin. Exp. Immunol. 54(1), 232–238 (1983).
   PubMed Web of Science ®Google Scholar
• Fabien N, Desbos A, Bienvenu J, Magdalou J. Autoantibodies directed against the UDP-glucuronosyltransferases in human autoimmune hepatitis. Autoimmun. Rev. 3(1), 1–9 (2004).
   PubMed Web of Science ®Google Scholar
• Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC. Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 4(2), 315–323 (1984).
   PubMed Web of Science ®Google Scholar
• Iijima Y, Kato T, Miyakawa H et al. Effect of interferon therapy on Japanese chronic hepatitis C virus patients with anti-liver/kidney microsome autoantibody type 1. J. Gastroenterol. Hepatol. 16(7), 782–788 (2001).
   PubMed Web of Science ®Google Scholar
• Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J. Exp. Med. 168(2), 801–806 (1988).
   PubMed Web of Science ®Google Scholar
• Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc. Natl Acad. Sci. USA 85(21), 8256–8260 (1988).
   PubMed Web of Science ®Google Scholar
• Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J. Clin. Invest. 83(3), 1066–1072 (1989).
   PubMed Web of Science ®Google Scholar
• Vergani D. LKM antibody: getting in some target practice. Gut 46(4), 449–450 (2000).
   PubMed Web of Science ®Google Scholar
• Manns MP, Johnson EF. Identification of human cytochrome P450s as autoantigens. Meth. Enzymol. 206, 210–220 (1991).
   PubMed Web of Science ®Google Scholar
• Kerkar N, Choudhuri K, Ma Y et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J. Immunol. 170(3), 1481–1489 (2003).
   PubMed Web of Science ®Google Scholar
• Muratori L, Parola M, Ripalti A et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 46(4), 553–561 (2000).
   PubMed Web of Science ®Google Scholar
• Vitozzi S, Djilali-Saiah I, Lapierre P, Alvarez F. Anti-soluble liver antigen/liver-pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity 35(8), 485–492 (2002).
   PubMed Web of Science ®Google Scholar
• Costa M, Rodríguez-Sánchez JL, Czaja AJ, Gelpí C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin. Exp. Immunol. 121(2), 364–374 (2000).
   PubMed Web of Science ®Google Scholar
• Lindgren S, Nilsson S, Nässberger L, Verbaan H, Wieslander J. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK). J. Gastroenterol. Hepatol. 15(4), 437–442 (2000).
   PubMed Web of Science ®Google Scholar
• Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 8(6), 1662–1666 (1988).
   PubMed Web of Science ®Google Scholar
• Muratori L, Cataleta M, Muratori P et al. Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. J. Immunol. Methods 187(2), 259–264 (1995).
   PubMed Web of Science ®Google Scholar
• Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 42(5), 721–726 (1998).
   PubMed Web of Science ®Google Scholar
• Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 377(9777), 1600–1609 (2011).
   PubMed Web of Science ®Google Scholar
• Metcalf JV, Bhopal RS, Gray J, Howel D, James OF. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int. J. Epidemiol. 26(4), 830–836 (1997).
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Miozzo M, Battezzati PM et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 363(9408), 533–535 (2004).
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Liu X, Xu C et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N. Engl. J. Med. 360(24), 2544–2555 (2009).
   PubMed Web of Science ®Google Scholar
• Mells GF, Floyd JA, Morley KI et al.; UK PBC Consortium; Wellcome Trust Case Control Consortium 3. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat. Genet. 43(4), 329–332 (2011).
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI. Molecular diagnostics of primary biliary cirrhosis. Expert Opin. Med. Diagn. 2, 621–634 (2008).
   PubMedGoogle Scholar
• Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J. Immunol. 138(10), 3525–3531 (1987).
   PubMed Web of Science ®Google Scholar
• Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet 1(7390), 827–831 (1965).
   PubMed Web of Science ®Google Scholar
• Homberg JC, Abuaf N, Bernard O et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology 7(6), 1333–1339 (1987).
   PubMed Web of Science ®Google Scholar
• Nakanuma Y, Harada K, Kaji K et al. Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies. Liver 17(6), 281–287 (1997).
   PubMedGoogle Scholar
• Muratori P, Muratori L, Gershwin ME et al. ‘True’ antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin. Exp. Immunol. 135(1), 154–158 (2004).
   PubMed Web of Science ®Google Scholar
• Moteki S, Leung PS, Coppel RL et al. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Hepatology 24(1), 97–103 (1996).
   PubMed Web of Science ®Google Scholar
• Gabeta S, Norman GL, Liaskos C et al. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J. Clin. Immunol. 27(4), 378–387 (2007).
   PubMed Web of Science ®Google Scholar
• Oertelt S, Rieger R, Selmi C et al. A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology 45(3), 659–665 (2007).
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N. Engl. J. Med. 353(12), 1261–1273 (2005).
   PubMed Web of Science ®Google Scholar
• Cunha LM, Bittencourt PL, Abrantes-Lemos CP et al. Prevalence of non-organ-specific autoantibodies in a rural community from northeastern Brazil: a population-based study. Hum. Immunol. 73(1), 70–74 (2012).
   PubMedGoogle Scholar
• Turchany JM, Uibo R, Kivik T et al. A study of antimitochondrial antibodies in a random population in Estonia. Am. J. Gastroenterol. 92(1), 124–126 (1997).
   PubMed Web of Science ®Google Scholar
• Shibata M, Onozuka Y, Morizane T et al. Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture. J. Gastroenterol. 39(3), 255–259 (2004).
   PubMed Web of Science ®Google Scholar
• Grimbert S, Johanet C, Bendjaballah F, Homberg JC, Poupon R, Beaugrand M. Antimitochondrial antibodies in patients with chronic hepatitis C. Liver 16(3), 161–165 (1996).
   PubMedGoogle Scholar
• Ramos-Casals M, Pares A, Jara LJ et al.; HISPAMEC Study Group. Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. J. Viral Hepat. 12(6), 648–654 (2005).
   PubMed Web of Science ®Google Scholar
• Floreani A, Baragiotta A, Leone MG, Baldo V, Naccarato R. Primary biliary cirrhosis and hepatitis C virus infection. Am. J. Gastroenterol. 98(12), 2757–2762 (2003).
   PubMed Web of Science ®Google Scholar
• Mitchison HC, Bassendine MF, Hendrick A et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 6(6), 1279–1284 (1986).
   PubMed Web of Science ®Google Scholar
• Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 348(9039), 1399–1402 (1996).
   PubMed Web of Science ®Google Scholar
• Liu H, Norman GL, Shums Z et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J. Autoimmun. 35(4), 436–442 (2010).
   PubMed Web of Science ®Google Scholar
• Christensen E, Crowe J, Doniach D et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78(2), 236–246 (1980).
   PubMed Web of Science ®Google Scholar
• Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N. Engl. J. Med. 308(1), 1–7 (1983).
   PubMed Web of Science ®Google Scholar
• Heseltine L, Turner IB, Fussey SP et al. Primary biliary cirrhosis. Quantitation of autoantibodies to purified mitochondrial enzymes and correlation with disease progression. Gastroenterology 99(6), 1786–1792 (1990).
   PubMed Web of Science ®Google Scholar
• Bogdanos DP, Liaskos C, Pares A et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 45(6), 1583; author reply 1583–1584 (2007).
   Google Scholar
• Van Norstrand MD, Malinchoc M, Lindor KD et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 25(1), 6–11 (1997).
   PubMed Web of Science ®Google Scholar
• Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am. J. Gastroenterol. 97(4), 999–1002 (2002).
   PubMed Web of Science ®Google Scholar
• Masuda J, Omagari K, Ohba K et al. Correlation between histopathological findings of the liver and IgA class antibodies to 2-oxo-acid dehydrogenase complex in primary biliary cirrhosis. Dig. Dis. Sci. 48(5), 932–938 (2003).
   PubMed Web of Science ®Google Scholar
• Omagari K, Kadokawa Y, Nakamura M et al. IgA class antibodies to 2-oxo-acid dehydrogenase complex are not predictive markers of histopathological progression in primary biliary cirrhosis. Autoimmunity 39(2), 107–112 (2006).
   PubMed Web of Science ®Google Scholar
• Brunner G, Klinge O. A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis). Dtsch. Med. Wochenschr. 112(38), 1454–1458 (1987).
   PubMed Web of Science ®Google Scholar
• Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am. J. Gastroenterol. 90(2), 247–249 (1995).
   PubMed Web of Science ®Google Scholar
• Szostecki C, Guldner HH, Netter HJ, Will H. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J. Immunol. 145(12), 4338–4347 (1990).
   PubMed Web of Science ®Google Scholar
• Szostecki C, Will H, Netter HJ, Guldner HH. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand. J. Immunol. 36(4), 555–564 (1992).
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. Autoantibodies from patients with primary biliary cirrhosis preferentially react with the amino-terminal domain of nuclear pore complex glycoprotein gp210. J. Exp. Med. 182(4), 1159–1162 (1995).
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Hohenuer H, Hitchman E, Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 110(3), 840–847 (1996).
   PubMed Web of Science ®Google Scholar
• Yang Z, Liang Y, Qin B et al. Clinical significance of conventional serum autoantibodies for various liver diseases in a Chinese population. Clin. Biochem. 54(3), 203–206 (2012).
   Google Scholar
• Rigopoulou EI, Davies ET, Pares A et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 54(4), 528–532 (2005).
   PubMed Web of Science ®Google Scholar
• Muratori P, Muratori L, Cassani F et al. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin. Exp. Immunol. 127(1), 172–175 (2002).
   PubMed Web of Science ®Google Scholar
• Luettig B, Boeker KH, Schoessler W et al. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. J. Hepatol. 28(5), 824–828 (1998).
   PubMed Web of Science ®Google Scholar
• Züchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 26(5), 1123–1130 (1997).
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Podda M, Battezzati PM et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J. Hepatol. 34(3), 366–372 (2001).
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Penner E, Battezzati PM et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43(5), 1135–1144 (2006).
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Klima A, Ranftler C et al. Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen. J. Cell. Biochem. 104(1), 27–37 (2008).
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Klima A, Komina O, Ranftler C, Invernizzi P, Penner E. Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies. Ann. NY Acad. Sci. 1109, 519–530 (2007).
   PubMed Web of Science ®Google Scholar
• Milkiewicz P, Buwaneswaran H, Coltescu C, Shums Z, Norman GL, Heathcote EJ. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin. Gastroenterol. Hepatol. 7(12), 1355–1360 (2009).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Kondo H, Mori T et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45(1), 118–127 (2007).
   PubMed Web of Science ®Google Scholar
• Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin. Gastroenterol. Hepatol. 2(12), 1116–1122 (2004).
   PubMed Web of Science ®Google Scholar
• Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin. Liver Dis. 26(1), 22–30 (2006).
   PubMed Web of Science ®Google Scholar
• Bambha K, Kim WR, Talwalkar J et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125(5), 1364–1369 (2003).
   PubMed Web of Science ®Google Scholar
• Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin. Liver Dis. 11(1), 31–39 (1991).
   PubMed Web of Science ®Google Scholar
• O’Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin. Liver Dis. 26(1), 3–21 (2006).
   PubMed Web of Science ®Google Scholar
• Yamada S, Ishii M, Liang LS, Yamamoto T, Toyota T. Small duct cholangitis induced by N-formyl l-methionine l-leucine l-tyrosine in rats. J. Gastroenterol. 29(5), 631–636 (1994).
   PubMed Web of Science ®Google Scholar
• Lichtman SN, Keku J, Clark RL, Schwab JH, Sartor RB. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 13(4), 766–772 (1991).
   PubMed Web of Science ®Google Scholar
• Chapman R, Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J. Gastroenterol. 14(21), 3350–3359 (2008).
   PubMed Web of Science ®Google Scholar
• Duerr RH, Targan SR, Landers CJ et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 100(5 Pt 1), 1385–1391 (1991).
   PubMed Web of Science ®Google Scholar
• Claise C, Johanet C, Bouhnik Y, Kapel N, Homberg JC, Poupon R. Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases. Liver 16(1), 28–34 (1996).
   PubMedGoogle Scholar
• Klein R, Klöppel G, Garbe W, Fintelmann V, Berg PA. Antimitochondrial antibody profiles determined at early stages of primary biliary cirrhosis differentiate between a benign and a progressive course of the disease. A retrospective analysis of 76 patients over 6–18 years. J. Hepatol. 12(1), 21–27 (1991).
   PubMed Web of Science ®Google Scholar
• Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 108(4), 1159–1166 (1995).
   PubMed Web of Science ®Google Scholar
• Mulder AH, Horst G, Haagsma EB, Kleibeuker JH, Kallenberg CG. Anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver disease. Adv. Exp. Med. Biol. 336, 545–549 (1993).
   PubMedGoogle Scholar
• Terjung B, Spengler U, Sauerbruch T, Worman HJ. “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 119(2), 310–322 (2000).
   PubMed Web of Science ®Google Scholar
• Roozendaal C, Van Milligen de Wit AW, Haagsma EB et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am. J. Med. 105(5), 393–399 (1998).
   PubMed Web of Science ®Google Scholar
• Bansi DS, Bauducci M, Bergqvist A et al. Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. Eur. J. Gastroenterol. Hepatol. 9(6), 575–580 (1997).
   PubMed Web of Science ®Google Scholar
• Pokorny CS, Norton ID, McCaughan GW, Selby WS. Anti-neutrophil cytoplasmic antibody: a prognostic indicator in primary sclerosing cholangitis. J. Gastroenterol. Hepatol. 9(1), 40–44 (1994).
   PubMed Web of Science ®Google Scholar
• Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 51(1), 120–127 (2002).
   PubMed Web of Science ®Google Scholar
• Karrar A, Broomé U, Södergren T et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 132(4), 1504–1514 (2007).
   PubMed Web of Science ®Google Scholar
• Fathman CG, Soares L, Chan SM, Utz PJ. An array of possibilities for the study of autoimmunity. Nature 435(7042), 605–611 (2005).
   PubMed Web of Science ®Google Scholar
• Iborra M, Bernuzzi F, Invernizzi P, Danese S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun. Rev. 11(5), 305–314 (2012).
   PubMed Web of Science ®Google Scholar
• Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J. Autoimmun. 32(3–4), 189–194 (2009).
   PubMed Web of Science ®Google Scholar
• Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA. miRNAs and related polymorphisms in rheumatoid arthritis susceptibility. Autoimmun. Rev. 11(9), 636–641 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang W, Ono Y, Miyamura Y, Bowlus CL, Gershwin ME, Maverakis E. T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. J. Autoimmun. 37(2), 71–78 (2011).
   PubMed Web of Science ®Google Scholar
• Bernuzzi F, Fenoglio D, Battaglia F et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J. Autoimmun. 35(3), 176–180 (2010).
   PubMed Web of Science ®Google Scholar
• Fu SM, Deshmukh US, Gaskin F. Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J. Autoimmun. 37(2), 104–112 (2011).
   PubMed Web of Science ®Google Scholar
• Hickman-Brecks CL, Racz JL, Meyer DM, LaBranche TP, Allen PM. Th17 cells can provide B cell help in autoantibody induced arthritis. J. Autoimmun. 36(1), 65–75 (2011).
   PubMed Web of Science ®Google Scholar
• Hintermann E, Holdener M, Bayer M et al. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. J. Autoimmun. 37(3), 242–253 (2011).
   PubMed Web of Science ®Google Scholar
• Naiyanetr P, Butler JD, Meng L et al. Electrophile-modified lipoic derivatives of PDC-E2 elicits anti-mitochondrial antibody reactivity. J. Autoimmun. 37(3), 209–216 (2011).
   PubMed Web of Science ®Google Scholar
• Lidar M, Lipschitz N, Agmon-Levin N et al. Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia. Clin. Rev. Allergy Immunol. 42(2), 238–246 (2012).
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun. Rev. 11(8), 593–595 (2012).
   PubMed Web of Science ®Google Scholar
• Juran BD, Lazaridis KN. Update on the genetics and genomics of PBC. J. Autoimmun. 35(3), 181–187 (2010).
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349(16), 1526–1533 (2003).
   PubMed Web of Science ®Google Scholar